Keynote 224 Results Kite

Keynote 224 Results Kite. Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. Neither kite nor board of public examinations is responsible for any inadvertent error that may have crept in.

Kite, general education department, govt of kerala. In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on.